Completed
PHASE4
INTERVENTIONAL
NCT01066052
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years. After 4 years of treatment, height in these girls will be compared with an historical control group of untreated girls with Turner Syndrome, matched for age and height at baseline.
Interventions
Name:
r-hGH
Type:
DRUG
Description:
Subcutaneous administration.
Primary Outcomes
Measure:
Height SDS at Year 4
TimeFrame:
Year 4
Description:
Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.
Trial Information
NCT ID
NCT01066052
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Merck KGaA, Darmstadt, Germany
Last Updated
December 15, 2025